BRIEF-Turnstone Biologics to Be Acquired by XOMA for $0.34/Share Plus Contingent Value Right-February 2024-www.financetom.com

BRIEF-Turnstone Biologics to Be Acquired by XOMA for $0.34/Share Plus Contingent Value Right

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BRIEF-Turnstone Biologics to Be Acquired by XOMA for $0.34/Share Plus Contingent Value Right

Jun 27, 2025 5:05 AM

June 27 (Reuters) - Turnstone Biologics Corp ( TSBX ):

* TURNSTONE BIOLOGICS CORP. ( TSBX ) ENTERS INTO AGREEMENT TO BE

ACQUIRED

BY XOMA ROYALTY CORPORATION FOR $0.34 IN CASH PER SHARE PLUS A

CONTINGENT VALUE RIGHT

* TURNSTONE BIOLOGICS CORP ( TSBX ) - DEAL VALUED AT $0.34 PER SHARE

PLUS

CVR

Source text:

Further company coverage:

Previous page： From Google to BCCI; here is a look at companies penalised by CCI Next page： Budget 2022: India Inc quizzes budget architects

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

From Google to BCCI; here is a look at companies penalised by CCI

Feb 3, 2022

Here is a look at some instances where the Competition Commission of India imposed penalties on big firms and sectors.

Budget 2022: India Inc quizzes budget architects

Feb 2, 2022

In this special episode of CNBC-TV18, ‘Budget Verdict’, India’s top CEOs will quiz the architects of Budget 2022. The first post-budget dialogue between the government and the industry.

IndiGo offers Vaxi Fare discount to vaccinated passengers; check details here

Feb 2, 2022

IndiGo is offering 10 percent discount on the base fare to passengers who have received one or both doses of a COVID-19 vaccine.

Safex Chemicals acquires Shogun Lifesciences; acquisition to boost FY23 sales

Feb 3, 2022

Safex Chemicals said the 8-acre plot acquired along with Shogun Lifesciences will be utilised to strengthen the supply chain of existing and future businesses. It will eventually add more facilities to set up multi-product formulation sections and enhance present aluminium phosphide production capabilities.